Year None20212020201920182017 Turning Point Therapeutics Announces Early Clinical Data for Repotrectinib in NTRK Fusion-Positive Advanced Solid Tumors Selected for Late-Breaker Plenary Presentation at 2021 AACR-NCI-EORTC Conference Sep 08, 2021 Turning Point Therapeutics to Participate In Upcoming Investor Conferences Sep 01, 2021 Turning Point Therapeutics Initiates TRIDENT-2 Clinical Study Investigating Repotrectinib-Trametinib Combination in KRAS G12D Mutated Advanced Solid Tumors Aug 16, 2021 Turning Point Therapeutics Granted Sixth Regulatory Designation for Repotrectinib Aug 11, 2021 Turning Point Therapeutics Reports Second-Quarter Financial Results, Provides Operational Updates Aug 09, 2021 Turning Point Therapeutics to Host Second Quarter 2021 Conference Call Jul 28, 2021 Turning Point Therapeutics Appoints Paolo Tombesi as Executive Vice President and Chief Financial Officer Jun 29, 2021 Turning Point Therapeutics Granted FDA Orphan Drug Designation for TPX-0022 in Gastric Cancer Jun 17, 2021 Turning Point Therapeutics to Participate in Goldman Sachs 42nd Annual Healthcare Conference Jun 01, 2021 Turning Point Therapeutics Names Former Celgene Chairman and CEO, Mark Alles, to Chair Its Board of Directors May 25, 2021 Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »
